Tonix Pharmaceuticals Holding Corp. (NASDAQ: TNXP) announced a major managed Medicare agreement for TONMYA® (cyclobenzaprine HCl sublingual tablets), adding approximately 9 million Medicare beneficiaries effective Jan. 1, 2027. Combined with previously announced commercial coverage agreements and broad Medicaid availability, the company said TONMYA will have pharmacy coverage reaching approximately 145 million covered lives, or 46% of the U.S. covered market, while discussions with additional commercial and Medicare payers continue.
Following the expanded coverage and positive launch metrics, Tonix plans to add 50 sales representatives by mid-third quarter 2026, increasing its commercial sales force to approximately 150 people. The company said it is also expanding marketing and medical affairs initiatives to increase awareness of TONMYA as a first-in-class, non-opioid treatment option for fibromyalgia.
Tonix Pharmaceuticals is a fully-integrated, commercial-stage biotechnology company focused on central nervous system (CNS) and immunology treatments in areas of high unmet medical need. TONMYA™ (cyclobenzaprine HCl sublingual tablets 2.8mg), the Company’s recently approved flagship medicine, is the first new treatment for fibromyalgia in more than 15 years. Tonix’s CNS commercial infrastructure supports its marketed products, including its acute migraine products, Zembrace® SymTouch® and Tosymra®. Tonix is maximizing the science behind TONMYA in Phase 2 clinical trials to evaluate its potential in major depressive disorder and acute stress disorder. In addition, the company’s CNS portfolio includes TNX-2900, which is Phase 2 ready for the treatment of Prader-Willi syndrome, a rare disease. Tonix is also advancing a pipeline of immunology programs, including monoclonal antibody TNX-4800 for Lyme disease prophylaxis and TNX-1500, a third-generation CD40 ligand inhibitor for the prevention of kidney transplant rejection.
This expansion of coverage is significant as it provides broader access to TONMYA, a non-opioid alternative for fibromyalgia patients. The company's ability to secure coverage for nearly half the U.S. market underscores the potential demand and acceptance of this treatment. For more details, visit the full press release at https://ibn.fm/tVAj3 and the company’s newsroom at https://ibn.fm/TNXP.
